Gilead announced that its new (PrEP) injectable has passed a Phase III clinical trial demonstrating the medication protected cisgender women from HIV in 100% of cases.
With zero infections the twice-yearly injectable has demonstrated its potential as an important new tool to help prevent HIV infections,
If testing continues to go as planned, it is expected the drug will hit the market in late 2025.
PrEP is widely regarded as one of the most effective means by which to prevent HIV -- lowering the risk of transmission through sex by upwards of 99% and through injections by 74%, according to the (CDC). More here